AbbVie Inc. (ABBV) Income Tax Expense
The tax expense for AbbVie Inc. (ABBV) is $2.36 Billion with a year-over-year change of +514.74%. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.
ABBV Tax Expense Chart
Current Tax Expense
$2.36B
$2.36 Billion
Year-over-Year Change
+514.74%
vs. $-570.00M prior year
Historical Data
17
Years of data available
Annual Tax Expense History
| Year | Tax Expense | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.36B | +$2.93B | +514.74% |
| 2024 | $-570.00M | $-1.95B | -141.39% |
| 2023 | $1.38B | $-255.00M | -15.63% |
| 2022 | $1.63B | +$192.00M | +13.33% |
| 2021 | $1.44B | +$2.66B | +217.65% |
| 2020 | $-1.22B | $-1.77B | -325.00% |
| 2019 | $544.00M | +$1.03B | +211.02% |
| 2018 | $-490.00M | $-2.91B | -120.26% |
| 2017 | $2.42B | +$487.00M | +25.22% |
| 2016 | $1.93B | +$430.00M | +28.65% |
| 2015 | $1.50B | +$906.00M | +152.27% |
| 2014 | $595.00M | $-609.00M | -50.58% |
| 2013 | $1.20B | +$754.00M | +167.56% |
| 2012 | $450.00M | +$215.00M | +91.49% |
| 2011 | $235.00M | $-423.00M | -64.29% |
| 2010 | $658.00M | $-655.80M | -49.92% |
| 2009 | $1.31B | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael